Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBLE: AZD0466 in Advanced Haematological Malignancies
NCT04865419Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Aug 2023
- Modality
- Nanoparticles, Small Molecules, Peptide-Drug Conjugates
- Countries
- 6
01
Overview
Phase 1, open-label trial of AZD0466 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (2 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Number of Participants With Dose-limiting Toxicity up to 35 days. Started Jun 2021; status: terminated.
02
Drugs
AZD0466
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04865419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865419.